SCHEMBL5049671

SCHEMBL5049671

C#CC(O)c1cc(OCc2ccc(F)cc2)c2c(c1)C(C)(C)CCC2(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.36
MAOA P21397 2/20 0.36
HPD P32754 1/20 0.34
CARM1 Q86X55 1/20 0.33
KMT2A Q03164 4/20 0.33
MEN1 O00255 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
MAPT P10636 2/20 0.32
POLB P06746 2/20 0.32
ALDH1A1 P00352 2/20 0.32
HPGD P15428 1/20 0.32
LMNA P02545 1/20 0.32
STAT3 P40763 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
RAB9A P51151 2/20 0.32
NPC1 O15118 1/20 0.32
ALOX5 P09917 1/20 0.32
RECQL P46063 1/20 0.32
HTR1A P08908 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5048450 0.90 MAOB (0.34) MAOBMAOAHPDKMT2AMAPT
SCHEMBL5043999 0.89 MAOB (0.38) MAOB
SCHEMBL5044048 0.88 NR4A2 (0.35) MAOBCARM1L3MBTL1RAB9A
SCHEMBL5047049 0.80 CYP26A1 (0.43) KMT2A
SCHEMBL6438536 0.80 MAOB (0.43) MAOBMAOAHPDKMT2AMEN1
SCHEMBL5050779 0.80 PARP10 (0.43) MAOB
SCHEMBL3052879 0.79 CYP26A1 (0.32)
SCHEMBL5047163 0.78 HDAC6 (0.41) KMT2AMEN1LMNA
SCHEMBL5048423 0.78 MAOA (0.37) MAOBMAOAHPDKMT2ARAB9A
SCHEMBL5050793 0.77 BRD4 (0.37) KMT2AMEN1L3MBTL1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US disclosed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG MAOB 2084/4885MAOA 2011/4885HPD 4268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.